Diffuse Cutaneous Systemic Sclerosis (1)

Scleroderma (1)

dcSSc (1)

Recruiting (1)

phase 1/phase 2 (1)

National Institute of Allergy and Infectious Diseases (NIAID) (1)

Immune Tolerance Network (ITN) (1)

PPD (1)

Rho Federal Systems Division, Inc. (1)

Seagen Inc. (1)

brentuximab vedotin (1)

placebo (1)

biological (1)

NIH (1)

Interventional (1)

dcssc

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recruiting

May 12, 2022